BackgroundCheck.run
Search For

Christian B Allan, 62San Mateo, CA

Known as:
Drchristian B Allan Allan B Christian Allan B Drchristian Allan B Christphr
Related to:
Michael John Anthony 75

Christian Allan Phones & Addresses

San Mateo, CA   

28892 Log Cabin Ln, Westover, MD 21871   

Brookeville, MD   

Montague, MA   

Hayward, CA   

Stockton, CA   

Somerset, MD   

3434 Glendora Dr, San Mateo, CA 94403   

Get Report
Control this profile

Mentions for Christian B Allan

Career records & work history

Medicine Doctors

Christian E. Allan

Specialties:
Gynecology
Work:
Christian E Allan MD
211 S Crapo St STE L, Mount Pleasant, MI 48858
989-7721213 (phone) 989-7727147 (fax)
Education:
Medical School
Ohio State University College of Medicine
Graduated: 1976
Procedures:
D & C Dilation and Curettage, Destruction of Benign/Premalignant Skin Lesions, Destruction of Lesions on the Anus, Hysterectomy, Ovarian Surgery, Skin Surgery, Skin Tags Removal, Tubal Surgery, Vaccine Administration, Vaginal Repair
Conditions:
Abnormal Vaginal Bleeding, Acne, Alopecia Areata, Breast Disorders, Candidiasis of Vulva and Vagina, Cervical Cancer, Contact Dermatitis, Dermatitis, Endometriosis, Female Infertility, Genital HPV, Hemorrhoids, Herpes Genitalis, Hypertension (HTN), Malignant Neoplasm of Female Genitourinary Organs, Menopausal and Postmenopausal Disorders, Ovarian Cancer, Ovarian Dysfunction, Plantar Warts, Polycystic Ovarian Syndrome (PCOS), Premenstrual Syndrome (PMS), Psoriasis, Rosacea, Skin Cancer, Tinea Unguium, Uterine Cancer, Uterine Leiomyoma, Varicose Veins
Languages:
English
Description:
Dr. Allan graduated from the Ohio State University College of Medicine in 1976. He works in Mount Pleasant, MI and specializes in Gynecology. Dr. Allan is affiliated with Mclaren Central Michigan and Midmichigan Medical Center Gratiot.
Christian Allan Photo 1

Christian Ellsworth Allan

Specialties:
Obstetrics & Gynecology
Gynecology
Education:
The Ohio State University(1976)

Resumes & CV records

Resumes

Christian Allan Photo 34

Head Of Cmc Operations

Location:
San Francisco, CA
Industry:
Biotechnology
Work:
Adc Therapeutics America
Head of Cmc Operations Abbvie Jan 2013 - 2017
Director, Global Cmc Program Management Abbott Biotherapeutics 2011 - 2012
Director, Global Cmc Program Management Regenerx Biopharmaceuticals, Inc. 2007 - 2011
Senior Director, Manufacturing, Formulation Development and Analytical Sciences Phiotech Solutions 2008 - 2011
Managing Partner and Founder Medimmune 1999 - 2006
Associate Director National Institutes of Health National Heart Lung and Blood Institute Laboratory of Biochemistry 1996 - 1999
Staff Fellow University of Massachusetts Amherst 1994 - 1996
Postdoctoral Research Associate Alameda Instruments 1989 - 1992
Team Leader and Chemist Trc Companies, Inc. 1987 - 1989
Research Associate
Education:
Cal State East Bay - College of Business & Economics
Bachelors, Bachelor of Science, Chemistry University of the Pacific
Doctorates, Doctor of Philosophy, Chemistry
Christian Allan Photo 35

Christian Allan

Publications & IP owners

Us Patents

Stabilized Liquid Anti-Rsv Antibody Formulations

US Patent:
7294336, Nov 13, 2007
Filed:
Feb 24, 2006
Appl. No.:
11/362267
Inventors:
Cynthia N. Oliver - N. Potomac MD, US
Erica Shane - McLean VA, US
Benjamin S. Isaacs - Andover MA, US
Christian B. Allan - Brookeville MD, US
Stephen T. Chang - Frederick MD, US
Assignee:
MedImmune, Inc. - Gaithersburg MD
International Classification:
A61K 39/395
A61K 39/42
US Classification:
4241301, 4241411, 4241471, 4241591
Abstract:
The present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

Stabilized Anti-Respiratory Syncytial Virus (Rsv) Antibody Formulations

US Patent:
7425618, Sep 16, 2008
Filed:
Jun 13, 2003
Appl. No.:
10/461863
Inventors:
Cynthia N. Oliver - N. Potomac MD, US
Christian B. Allan - Brookeville MD, US
Stephen T. Chang - Frederick MD, US
Assignee:
Medimmune, Inc. - Gaithersburg MD
International Classification:
C12P 21/08
US Classification:
5303871, 5303881, 5303891, 4241591
Abstract:
The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.

High Affinity Antibodies Against Hmgb1 And Methods Of Use Thereof

US Patent:
7585504, Sep 8, 2009
Filed:
Oct 21, 2005
Appl. No.:
11/254679
Inventors:
Herren Wu - Boyds MD, US
Christian B. Allan - Brookeville MD, US
Changshou Gao - Potomac MD, US
Ling-Ling An - Boyds MD, US
Peter Kiener - Potomac MD, US
Anthony Coyle - Washington DC, US
Assignee:
MedImmune, LLC - Gaithersburg MD
International Classification:
A61K 39/395
US Classification:
4241421, 4241581, 53038815, 53038823
Abstract:
Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

Anti-Il-9 Antibody Formulations

US Patent:
7691379, Apr 6, 2010
Filed:
Apr 12, 2005
Appl. No.:
11/105268
Inventors:
Christian B. Allan - Brookeville MD, US
Assignee:
Medimmune, LLC - Gaithersburg MD
International Classification:
A61K 39/395
C07K 16/00
US Classification:
4241451, 53038823
Abstract:
The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to an IL-9 polypeptide, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to an IL-9 polypeptide, which formulations are substantially free of surfactants, sugars, sugar alcohols, amino acids other than histidine (preferably with pKa values of less than 5 and above 7), and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating a disease or disorder associated with or characterized by aberrant expression and/or activity of an IL-9 polypeptide, a disease or disorder associated with or characterized by aberrant expression and/or activity of the IL-9R or one or more subunits thereof, an autoimmune disease, an inflammatory disease, a proliferative disease, or an infection (preferably, a respiratory infection), or one or more symptoms thereof, utilizing the liquid formulations of the present invention.

Stabilized Liquid Anti-Rsv Antibody Formulations

US Patent:
7785592, Aug 31, 2010
Filed:
Oct 1, 2007
Appl. No.:
11/906543
Inventors:
Cynthia N. Oliver - North Potomac MD, US
Erica Shane - McLean VA, US
Benjamin S. Isaacs - Andover MA, US
Christian B. Allan - Brookeville MD, US
Stephen T. Chang - Frederick MD, US
Assignee:
MedImmune, LLC - Gaithersburg MD
International Classification:
A61K 39/395
A61K 39/40
A61K 39/42
C07K 16/00
US Classification:
4241331, 4241421, 4241471, 4241591, 5303871, 5303873, 5303881, 53038815, 5303883
Abstract:
The present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

Stabilized Liquid Anti-Rsv Antibody Formulations

US Patent:
8007793, Aug 30, 2011
Filed:
Jun 16, 2010
Appl. No.:
12/817097
Inventors:
Cynthia N. Oliver - North Potomac MD, US
Erica Shane - McLean VA, US
Benjamin S. Isaacs - Andover MA, US
Christian B. Allan - Brookeville MD, US
Stephen T. Chang - Frederick MD, US
Assignee:
MedImmune, LLC - Gaithersburg MD
International Classification:
A61K 39/395
A61K 39/42
US Classification:
4241301, 4241411, 4241471, 4241591
Abstract:
The present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

High Affinity Antibodies Against Hmgb1 And Methods Of Use Thereof

US Patent:
8153131, Apr 10, 2012
Filed:
Aug 3, 2009
Appl. No.:
12/534217
Inventors:
Herren Wu - Boyds MD, US
Christian Allan - Brookeville MD, US
Changshou Gao - Potomac MD, US
Ling-Ling An - Boyds MD, US
Peter Kiener - Potomac MD, US
Anthony Coyle - Washington DC, US
Assignee:
MedImmune, LLC - Gaithersburg MD
International Classification:
A61K 39/395
US Classification:
4241451, 53038823
Abstract:
Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

Integrated Approach For Generating Multidomain Protein Therapeutics

US Patent:
8309690, Nov 13, 2012
Filed:
Jun 30, 2006
Appl. No.:
11/993680
Inventors:
Christian Allan - Brookeville MD, US
Herren Wu - Boyds MD, US
Jeffrey Swers - Rockville MD, US
William Dall'Acqua - Gaithersburg MD, US
Assignee:
MedImmune, LLC - Gaithersburg MD
International Classification:
C07K 16/00
US Classification:
5303873, 4241301
Abstract:
The invention provides method for therapeutic protein drug development that incorporates therapeutic and/or formulation and/or manufacturing considerations in the early screening process. The approach involves screening a plurality of different variants of a domain that have been determined to have the desired therapeutic property to identify one or more variants that have desired therapeutic and/or formulation characteristics, and constructing the full multidomain proteins using the identified domain variants. The present invention also provides a method for determining the shelf life of multidomain proteins in formulations. The method comprises determining a thermal denaturation and/or renaturation curve of a domain of the protein whose unfolding leads to aggregation of the protein in a solution. The method evaluates the shelf life of the multidomain protein based on the denaturation/renaturation curve. The invention also provides methods for engineering multidomain proteins to improve their therapeutic and/or formulation characteristics.

Isbn (Books And Publications)

Life Without Bread: How A Low-Carbohydrate Diet Can Save Your Life

Author:
Christian Allan
ISBN #:
0658001701

Possible Relatives

Cynthia L Allan  David R Allan  Deanna J Allan  Debbie E Allan  Dana L Allan  Aaron W Allan  Deidre M Allan  Christian M Johnson  Christian White  Christian W Jones 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.